Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...

Biofrontera Inc. reports a record $37.3M in 2024 revenue, FDA milestones, and strategic growth plans for 2025.

Scpharmaceuticals (($SCPH)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for ...

Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company ...

Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM), ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

The Reserve Bank of India has accorded its approval on March 21, 2025 for acquisition of shareholding of up to 100% of the ...

Mr. Anurag Mantri, Executive Director & Group CFO of Jindal Stainless Limited has tendered his resignation from the services ...